Safety and Tolerability of Ubrogepant for the Acute Treatment of Migraine in Participants Taking Atogepant for the Preventive Treatment of Episodic Migraine: Results from the TANDEM Trial

被引：0
|
作者：
Ailani, Jessica [1 ]
Lipton, Richard B. [2 ]
Blumenfeld, Andrew M. [3 ]
He, Molly Yizeng [4 ]
Smith, Jonathan H. [5 ]
Trugman, Joel M. [4 ]
Ferreira, Rosa de Abreu [4 ]
Brand-Schieber, Elimor [4 ]
机构：
[1] Georgetown Univ Hosp, Washington, DC 20007 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Headache Ctr Southern Calif, Carlsbad, CA USA
[4] AbbVie, Madison, NJ 07940 USA
[5] AbbVie, N Chicago, IL USA
来源：
CEPHALALGIA | 2023年 / 43卷 / 1supp期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IHC23-LBAP
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Long-term Safety and Tolerability of Atogepant: Once Daily Dosing Over one Year for the Preventive Treatment of Migraine
    Ashina, M.
    Tepper, S.
    Reuter, U.
    Blumenfeld, A.
    Hutchinson, S.
    Xia, J.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 152 - 152
  • [42] Safety and tolerability of frovatriptan during acute treatment of migraine
    Spierings, EL
    HEADACHE, 2005, 45 (06): : 812 - 812
  • [43] Efficacy and Tolerability of Rizatriptan for the Treatment of Acute Migraine in Patients Taking Topiramate for Migraine Prophylaxis
    Seeburger, J. L.
    Cady, R. K.
    Winner, P.
    MacGregor, A.
    Valade, D.
    Ge, Y.
    Zhang, Y.
    Hustad, C.
    Strickler, N.
    Schaefer, E.
    Harper-Mozley, L.
    Fan, X.
    Hewitt, D.
    Ho, T.
    Connor, K. M.
    HEADACHE, 2010, 50 : S33 - S33
  • [44] Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
    Schwedt, Todd J.
    Lipton, Richard B.
    Ailani, Jessica
    Silberstein, Stephen D.
    Tassorelli, Cristina
    Guo, Hua
    Lu, Kaifeng
    Dabruzzo, Brett
    Miceli, Rosa
    Severt, Lawrence
    Finnegan, Michelle
    Trugman, Joel M.
    CEPHALALGIA, 2022, 42 (01) : 3 - 11
  • [45] Atogepant significantly reduces mean monthly migraine days in the phase 3 trial (ADVANCE) for the preventive treatment of migraine
    Ailani, J.
    Lipton, R. B.
    Goadsby, P. J.
    Guo, H.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2021, 61 : 99 - 100
  • [46] Real-world effectiveness of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA preventive: Results from the COURAGE study
    Lipton, R. B.
    Engstrom, E.
    Serrano, D.
    Davis, L.
    Sommer, K.
    Contreras-De Lama, J.
    Hutchinson, S.
    HEADACHE, 2022, 62 : 157 - 158
  • [47] Real-World Effectiveness of Ubrogepant for the Acute Treatment of Migraine in Combination With OnabotulinumtoxinA Preventive: Results From the COURAGE Study
    Lipton, Richard B.
    Engstrom, Ella
    Serrano, Daniel
    Davis, Linda
    Sommer, Katherine
    Contreras-De Lama, Janette
    Hutchinson, Susan
    TOXICON, 2022, 214 : S65 - S66
  • [48] Preventive Oral Treatment of Episodic Migraine: An Overview
    Ranganathan, Lakshmi N.
    Ramamurthy, Guhan
    Kanthimathinathan, Shunmugasundaram
    NEUROLOGY INDIA, 2021, 69 : S51 - S58
  • [49] Fremanezumab as a preventive treatment for episodic and chronic migraine
    Bigal, Marcelo E.
    Walter, Sarah
    Rapoport, Alan M.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (08) : 719 - 728
  • [50] Long-term safety and tolerability of atogepant following once daily dosing over 1 year for the preventive treatment of migraine
    Ashina, M.
    Tepper, S. J.
    Reuter, U.
    Blumenfeld, A. M.
    Hutchinson, S.
    Xia, J.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2021, 61 : 95 - 96
12345